The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Placental Growth Factor (PlGF) and Its Receptor Flt‐1 (VEGFR‐1): Novel Therapeutic Targets for Angiogenic Disorders
Abstract
A bstract: Efforts to therapeutically stimulate or inhibit vessel growth have been primarily focused on vascular endothelial growth factor (VEGF) and its receptor VEGFR‐2 (Flk‐1), while little attention has been devoted to the therapeutic potential for angiogenic disorders of placental growth factor (PlGF), a VEGF family member, and its receptor VEGFR‐1 (Flt‐1). However, recent developments and insights could shift that focus to P1GF and Flt‐1. Indeed, PlGF stimulated angiogenesis and collateral growth in ischemic heart and limb with at least a comparable efficiency to VEGF and did not cause side effects associated with VEGF, such as edema or hypotension. An anti‐Flt‐1 antibody suppressed neovascularization in tumors and ischemic retina, and angiogenesis and inflammatory joint destruction in arthritis. The anti‐Flt‐1 antibody also reduced atherosclerotic plaque growth and vulnerability, but the atheroprotective effect was not due to reduced plaque neovascularization. The anti‐inflammatory effects of the anti‐Flt‐1 antibody were attributable to a reduced mobilization of bone marrow‐derived myeloid progenitors into the peripheral blood, a reduced mobilization/differentiation (and impaired infiltration) of Flt‐1‐expressing leukocytes into inflamed tissues, and a defective activation of myeloid cells. Thus, PlGF and Flt‐1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationRole of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Cited by
Cursiefen, C., Chen, L., Borges, L. P., Jackson, D. G., Cao, J., Radziejewski, C. H., D'Amore, P. A., Dana, M. R., Wiegand, S. J., & Streilein, J. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420465 · Cited by 1,059
VEGF-receptor signal transduction
Cross, M. J., Dixelius, J., Matsumoto, T., & Claesson-Welsh, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00193-2 · Cited by 864
Mechanisms of macular edema: Beyond the surface
Daruich, A., Matet, A., Moulin, A., Kowalczuk, L., Nicolas, M., Sellam, A., Rothschild, P.-R., Omri, S., Gélizé, E., Jonet, L., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.006 · Cited by 708
Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis
Sluimer, J. C., & Daemen, M. J. (2009) · The Journal of Pathology · doi:10.1002/path.2518 · Cited by 367
Vascular Biology and the Skeleton
Brandi, M. L., & Collin-Osdoby, P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050917 · Cited by 338
Metadata
- Authors
- LUTTUN, A., TJWA, M., & CARMELIET, P.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2002-12
- Volume
- 979
- Issue
- 1
- Pages
- 80-93
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2155739651
- Cited by
- 202
- References
- 3
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Placental Growth Factor (PlGF) and Its Receptor Flt‐1 (VEGFR‐1): Novel Therapeutic Targets for Angiogenic Disorders. https://app.cochat.ai/papers/10.1111/j.1749-6632.2002.tb04870.x
- The paper
- LUTTUN, A., TJWA, M., & CARMELIET, P. (2002). Placental Growth Factor (PlGF) and Its Receptor Flt‐1 (VEGFR‐1): Novel Therapeutic Targets for Angiogenic Disorders. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2002.tb04870.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.